A Chinese medicine composition for treating chronic atrophic gastritis and its extract and application

Abstract

The present invention provides a Chinese medicine composition and extract and application for treating chronic atrophic gastritis. A Chinese medicine composition for treating chronic atrophic gastritis comprises the following Chinese medicinal materials in weight proportion: 12-18g of Blumea Balsamifera, 15-25g of Radix Achyranthis Bidentatae, 15-25g of Rhizoma Cibotii, 8-12g of Agastache rugosa, 8-12g of Alpinia officinalis, 2-4g of Panax notoginseng, and 2-4g of Aquilaria sinensis. Compared with the existing Chinese medicine formula, the Chinese medicine formula of the present invention treats chronic atrophic gastritis, and the symptom relief of the patient is very obvious, and the degree of atrophy and functional state of the patient's gastric mucosa are better improved, and the quality of life of patients with chronic atrophic gastritis can be better improved. It has a wide range of application and can be applied to patients with chronic atrophic gastritis of different constitutions or syndromes.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition and extract for treating chronic atrophic gastritis and application thereof. Background Art

[0002] Chronic atrophic gastritis is a disease characterized by atrophy of the gastric mucosa and reduction of intrinsic glands, with or without intestinal metaplasia (or) pseudopyloric metaplasia as the main pathological manifestations. The World Health Organization has defined chronic atrophic gastritis as a precancerous lesion of gastric cancer. The current treatment measures adopted by Western medicine mainly include symptomatic treatment such as eradication of Hp, protection of gastric mucosa, and promotion of gastrointestinal motility, but Western medicine treatment is not specific, has great side effects, and cannot be cured. Summary of the invention

[0003] In view of this, the present invention provides a Chinese medicine composition and extract and application thereof for treating chronic atrophic gastritis.

[0004] The technical solution of the present invention is achieved in this way:

[0005] A traditional Chinese medicine composition for treating chronic atrophic gastritis comprises the following traditional Chinese medicines in the following weight proportions: 12-18g of Blumea balsamifera, 15-25g of Radix Codonopsis pilosulae, 15-25g of Prunus mume, 8-12g of Patchouli, 8-12g of Alpinia officinalis, 2-4g of Panax notoginseng, and 2-4g of Aquilaria wood.

[0006] A preferred embodiment is that the Chinese medicine composition for treating chronic atrophic gastritis comprises the following Chinese medicinal materials in weight proportion: 14-16g of Blumea Balsamifera, 19-21g of Radix Achyranthis Bidentatae, 19-21g of Rhizoma Cibotii, 9-11g of Herba Patchouli, 9-11g of Alpinia Officinalis, 2.5-3.5g of Panax Notoginseng, and 2.5-3.5g of Aquilaria Sinensis. A more preferred embodiment is that the Chinese medicine composition for treating chronic atrophic gastritis comprises the following Chinese medicinal materials in weight proportion: 15g of Blumea Balsamifera, 20g of Radix Achyranthis Bidentatae, 20g of Rhizoma Cibotii, 10g of Herba Patchouli, 10g of Herba Patchouli, 3g of Panax Notoginseng, and 3g of Aquilaria Sinensis.

[0007] A further solution is a traditional Chinese medicine composition for treating chronic atrophic gastritis, which also includes reed root and chicken's gizzard lining. The traditional Chinese medicine composition includes the following traditional Chinese medicines in the following weight proportions: 12-18g of Blumea balsamifera, 15-25g of Radix Achyranthis Bidentatae, 15-25g of Rhizoma Cyperi, 8-12g of Patchouli, 8-12g of Alpinia officinarum, 2-4g of Panax notoginseng, 2-4g of Aquilaria woodis, 8-12g of reed root, and 8-12g of chicken's gizzard lining.

[0008] A preferred embodiment is that the Chinese medicine composition for treating chronic atrophic gastritis is composed of the following Chinese medicinal materials in weight proportion: 14-16g of Blumea Balsamifera, 19-21g of Radix Achyranthis Bidentatae, 19-21g of Rhizoma Cibotii, 9-11g of Herba Patchouli, 9-11g of Alpinia Officinalis, 2.5-3.5g of Radix Notoginseng, 2.5-3.5g of Aquilaria Sinensis, 9-11g of Rhizoma Phragmites, and 9-11g of Gizzard Gizzard. A more preferred embodiment is that the Chinese medicine composition for treating chronic atrophic gastritis is composed of the following Chinese medicinal materials in weight proportion: 15g of Blumea Balsamifera, 20g of Radix Achyranthis Bidentatae, 20g of Rhizoma Cibotii, 10g of Herba Patchouli, 10g of Gizzard Gizzard, 3g of Radix Notoginseng, 3g of Aquilaria Sinensis, 10g of Rhizoma Phragmites, and 10g of Gizzard Gizzard.

[0009] A traditional Chinese medicine extract for treating chronic atrophic gastritis is prepared from the traditional Chinese medicine composition of the invention.

[0010] A further solution is a method for preparing the Chinese medicine extract, which comprises weighing each component according to the Chinese medicine formula, grinding the agarwood into powder, adding water to other components until the raw medicine is covered, soaking for 30 to 40 minutes, boiling over high heat, then simmering over low heat for 20 to 30 minutes after boiling, repeating the decocting 2 to 3 times, mixing the medicinal juice, adding the agarwood powder, and stirring to obtain the extract.

[0011] The Chinese medicine composition or the Chinese medicine extract of the present invention is used in preparing medicine for treating atrophic gastritis.

[0012] In a further embodiment, the Chinese medicine composition or the Chinese medicine extract of the present invention is used in the preparation of a drug for treating chronic atrophic gastritis.

[0013] The Chinese medicine formula of the present invention comprises the following: Artemisia selengensis has the functions of regulating qi and relieving pain, dispelling wind and dampness, inducing sweat and removing phlegm; Rhizoma Atractylodis Macrocephala has the functions of clearing away heat and detoxicating, dispersing blood stasis and relieving swelling; Fructus Cynoglossi has the functions of invigorating the spleen, replenishing qi and nourishing yin, and has the functions of invigorating qi without being dry, and replenishing qi without promoting heat; the above three medicines are collectively monarch medicines, and have the functions of promoting blood circulation and dispersing blood stasis, regulating qi and relieving pain, invigorating the spleen and nourishing yin, and clearing away heat and removing dampness; the course of chronic atrophic gastritis is relatively long, and a pathological state of phlegm and blood stasis and deficiency of vital energy will occur if the disease is treated for a long time; Rhizoma Atractylodis Macrocephalae has the functions of removing "phlegm and blood stasis toxins", and Fructus Cynoglossi has the functions of replenishing vital energy; and the three medicines are used together to play the role of dispelling evil without hurting the vital energy. Patchouli is aromatic and can remove dampness and turbidity, while Alpinia officinalis warms the stomach and relieves pain, warms the spleen yang and removes dampness and turbidity, and promotes the function of spleen and stomach transportation and transformation. The spleen and stomach are located in the middle jiao and are the hub of the human body. When the spleen and stomach transportation and transformation are normal, the qi movement rises and falls in an orderly manner, and the yin and yang are in harmony; Agarwood regulates qi and can regulate qi stagnation, while warming the middle and relieving pain; Panax notoginseng can promote blood circulation and dissipate blood stasis, and dissipate blood stasis without hurting the body; Agarwood combined with Panax notoginseng can regulate qi, dissipate blood stasis and relieve pain, and the evil qi in qi and blood can be eliminated at the same time. The above four medicines are all ministerial medicines, which have the effects of warming yang and removing turbidity, regulating qi, dispersing blood stasis and relieving pain. The monarch and ministerial medicines work synergistically, playing the effects of strengthening the spleen and warming yang, replenishing qi and nourishing yin, regulating qi and relieving pain, clearing heat and removing dampness and turbidity, and promoting blood circulation and dispersing blood stasis, and have significant effects in treating chronic atrophic gastritis. Reed root nourishes yin, produces body fluid and relieves restlessness; chicken gizzard lining nourishes the spleen, nourishes the stomach and eliminates accumulation. Patients with chronic atrophic gastritis often experience symptoms such as irritability and poor appetite. Reed root and chicken gizzard lining can clear away heat and relieve restlessness, nourish the stomach and eliminate accumulation, and as adjuvants, they also play an important role. The whole prescription can be used for both cold and hot, attack and supplement, and harmonize qi, blood, yin and yang. It has a wide range of applications for patients with chronic atrophic gastritis of different constitutions or syndromes. This prescription can regulate the gastrointestinal tract, promote gastrointestinal motility, improve the ascending and descending functions of the spleen and stomach, improve atrophic gastric mucosa, and has a good repair effect on gastric mucosal damage caused by various factors, better block the further deterioration of chronic atrophic gastritis, and improve the efficacy of treating chronic atrophic gastritis.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] Compared with the existing Chinese medicine formula, the Chinese medicine formula of the present invention has the advantages of treating chronic atrophic gastritis, significantly relieving the symptoms of patients, better improving the degree of gastric mucosal atrophy and functional state of patients, and better improving the quality of life of patients with chronic atrophic gastritis, and having a wide range of applications. Secondly, the Chinese medicine formula of the present invention harmonizes qi, blood, yin and yang, has a wide range of applications, and can be applied to patients with chronic atrophic gastritis of different constitutions or syndromes. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is the endoscopic findings of Case 1 before treatment.

[0017] Figure 2 This is the attached figure of pathological examination of Case 1 before treatment.

[0018] Figure 3 This is the attached picture of gastroscopy findings after treatment of Case 1.

[0019] Figure 4 This is the attached figure of pathological examination of Case 2 before treatment.

[0020] Figure 5 This is the attached picture of gastroscopy after treatment of Case 2.

[0021] Figure 6 This is the attached figure of pathological examination of Case 2 after treatment. DETAILED DESCRIPTION

[0022] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.

[0023] Example

[0024] Chinese medicine formula: 15g of Ailanthus balsamiferus, 20g of Radix Achyranthis Bidentatae, 20g of Rhizoma Cibotii, 10g of Herba Patchouli, 10g of Alpinia officinalis, 3g of Panax notoginseng, 3g of Aquilaria sinensis, 10g of Phragmites australis, and 10g of Gallus gallus domestica. Weigh out each component according to the formula, grind the aquilaria sinensis into powder, add water to other components until the raw medicine is covered, soak for 30 minutes, turn to high heat and boil, turn to low heat and simmer for 20 to 30 minutes after boiling, and boil 150ml of the juice, repeat the decoction twice, and mix the two juices to 300ml, add the aquilaria sinensis powder and stir.

[0025] Application Examples

[0026] Case 1: Wang, female, 32 years old. First visit on August 20, 2021, complained of "repeated upper abdominal distension and discomfort for half a year". The current symptoms are upper abdominal distension and discomfort, especially after eating, poor appetite, and poor sleep at night. The tongue is pale red, the fur is thin and white, and the pulse is stringy. August 10, 2021 (Hainan Provincial People's Hospital) Gastroscopy: chronic atrophic gastritis C3. August 12, 2021 (Hainan Provincial People's Hospital) Pathology: (Gastric Antrum) Chronic atrophic gastritis, inflammation (++), activity (+), intrinsic glandular reduction (+), glandular epithelial intestinal metaplasia (-). Physical examination: clear mind, good spirit, generally good, whole abdomen soft, no tenderness and rebound pain. Western medicine diagnosis: chronic atrophic gastritis; Chinese medicine diagnosis: stomach distension; syndrome differentiation is spleen deficiency and qi stagnation syndrome. The patient was given one course of oral Chinese medicine compound according to the embodiment of the present invention. On the second visit on September 17, 2021, the patient's above symptoms were improved, and he had upper and middle abdominal distension when eating too much; after the follow-up visit and oral administration of the Chinese medicine compound of the present invention for 5 courses, the patient's clinical symptoms completely disappeared, without obvious discomfort, and his appetite and sleep were good, and his bowel movements were normal; the patient was asked to have a follow-up gastroscopy, and on August 30, 2022 (Hainan Provincial Hospital of Traditional Chinese Medicine), the gastroscopy showed chronic superficial gastritis. From the patient's clinical symptoms and gastroscopy results, it can be confirmed that the patient's chronic atrophic gastritis has been cured, and the TCM syndrome score has decreased by ≥95%.

[0027] Case 2: Lin, male, 35 years old, first diagnosed on July 17, 2021, complaining of "repeated upper abdominal pain for more than 1 year". The current symptoms are upper abdominal pain, distending pain, occasional acid reflux, obvious after eating, poor appetite, general sleep, pale red tongue, white and greasy fur, and stringy pulse. Gastroscopy at Hainan Provincial People's Hospital showed "chronic atrophic gastritis" (not reported); 2021-03-29 (Hainan Provincial People's Hospital) Pathology: (gastric antrum gastric angle) chronic atrophic gastritis, inflammation (++), activity (-), intrinsic glandular reduction (+), glandular epithelial intestinal metaplasia (++), focal glandular epithelial atypical changes. Western medicine and Chinese patent medicine (specific unknown) were given for treatment, but no significant improvement was seen. Western medicine diagnosis: chronic atrophic gastritis; Chinese medicine diagnosis: gastric distension; syndrome differentiation is spleen deficiency and qi stagnation syndrome. The patient was given one course of oral administration of the Chinese medicine compound of the embodiment of the present invention. On the second visit on August 14, 2021, the patient's above symptoms were improved, and he had upper and middle abdominal distension when eating too much; after 5 courses of oral administration of the Chinese medicine compound of the present invention, the patient's clinical symptoms completely disappeared, with no obvious discomfort, and good appetite and sleep. On August 5, 2022 (Hainan Provincial Hospital of Traditional Chinese Medicine) Gastroscopy: Atrophic gastritis C1 with antral erosion (combined with pathology). On August 5, 2022 (Hainan Provincial Hospital of Traditional Chinese Medicine) Pathology: (Gastric Antrum) Chronic atrophic gastritis (atrophy 2+, inflammation 2+, activity 1+). From the patient's clinical symptoms, it can be confirmed that the patient has recovered clinically, and the TCM syndrome score has decreased by ≥95%.

[0028] Clinical research example

[0029] 1. Collect basic case information

[0030] A total of 80 patients with chronic atrophic gastritis diagnosed by endoscopic biopsy pathology who met the diagnostic and inclusion criteria were collected. After exclusion according to the exclusion criteria, a total of 75 valid cases were found.

[0031] Age range: 18 to 70 years old.

[0032] There are 36 males and 39 females.

[0033] 2. Inclusion criteria

[0034] ①Meet the diagnostic criteria for chronic atrophic gastritis; ②Patients aged 18 to 70 years old; ③Voluntarily accept the survey and sign the informed consent form; ④No contraindications to endoscopic examination. At the same time, meet ①, ②, and ③.

[0035] 3. Exclusion criteria

[0036] ① Diagnosed with peptic ulcer, gastric cancer, chronic cholecystitis and other diseases with similar symptoms; ② Gastric mucosal dysplasia or suspected cancer; ③ Chronic non-atrophic gastritis; ④ Helicobacter pylori positive; ⑤ Previous history of gastrointestinal surgery; ⑥ Severe damage to important organs; ⑦ Accompanied by primary diseases such as autoimmune diseases; ⑧ Severe mental or psychological abnormalities; ⑨ Pregnant or lactating women; ⑩ Malignant hypertension.

[0037] 4. Elimination criteria

[0038] ① Those who are not eligible for inclusion after being included. ② Those who do not take medication as directed by the doctor, or take other medications that affect the clinical effect of the medication while taking medication as directed by the doctor. ③ Those who do not answer the researcher's questions truthfully, resulting in non-objective data or violation of statistical principles.

[0039] 5. Shedding Standard

[0040] ① Patients who voluntarily withdraw from the clinical study due to their subjective will. ② Women who become pregnant unexpectedly while taking the study drug. ③ Patients who have serious adverse drug reactions and the researchers cannot require the patients to continue to participate in the trial. ④ Patients whose data collection is incomplete or who lose contact or die unexpectedly during the study.

[0041] 6. Termination criteria

[0042] ① Regardless of which group of patients have adverse reactions that affect their health, the treatment should be terminated if the treatment provider believes that the treatment should be terminated. ② When the patient requests a change or refuses the original treatment plan due to unsatisfactory efficacy, the doctor should take the initiative to terminate the clinical research. ③ When other major diseases suddenly occur and endanger the patient's life, the physician should take the initiative to terminate the treatment and arrange for the patient to receive treatment for the major disease in a timely manner.

[0043] 7. Clinical research strategies and methods

[0044] 7.1 Dosage Regimen

[0045] 1) Treatment group:

[0046] Prescription: 15g of Artemisia argyi, 20g of Rhizoma Cibotii, 20g of Rhizoma Cibotii, 10g of Agastache rugosa, 10g of Alpinia officinalis, 3g of Panax notoginseng, 3g of Aquilaria wood, 10g of Phragmites australis, and 10g of Chicken Gizzard Stone.

[0047] Decoction method: Weigh out each component according to the formula. Except for grinding the agarwood into powder, add water to the other components until the raw herbs are covered. Soak for 30 minutes, then turn to high heat and boil. After boiling, turn to low heat and simmer for 20 to 30 minutes. Take 150ml of the medicine juice. Decoction each dose of medicine twice. Mix the two juices into 300ml. Add the agarwood powder and stir.

[0048] Dosage: Oral administration, twice a day, 150 ml of liquid each time, one dose a day, taken warm 1 hour after breakfast and dinner.

[0049] Treatment course: 4 weeks is one course of treatment, take 6 courses in total (stop taking when cured).

[0050] 2) Control group:

[0051] Drug: Folic acid tablets (Specification: 5 mg / tablet, Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.)

[0052] Dosage: 5 mg / time, 3 times / day, orally half an hour after meal.

[0053] Treatment course: 4 weeks is one course of treatment, and 6 courses are required.

[0054] During the medication period, both groups of patients were not allowed to take other drugs for the treatment of the disease or drugs that affect the efficacy of the drugs in this study. The doctors patiently answered the patients' questions, let the patients trust the doctors, and encouraged their confidence in overcoming the disease. At the same time, the two groups of patients were advised to eat a light diet and try to avoid spicy, raw, cold, hard, pickled, greasy, expired and high-starch foods. Before going to bed, you can raise the head of the bed by about 15 cm. Avoid staying up late and exercise moderately to enhance your body's immunity.

[0055] 7.2 Observation indicators

[0056] 1) Safety observation

[0057] ① General information: name, gender, age.

[0058] ②Record vital signs (body temperature, respiration, blood pressure, heart rate) and adverse drug reactions.

[0059] ③ Routine examination: one examination before and after treatment (electrocardiogram, three major routine tests, liver and kidney function).

[0060] 2) Observation of therapeutic efficacy

[0061] ① TCM symptom assessment indicators

[0062] Main symptoms: bloating, stomach pain, belching, poor appetite

[0063] Secondary symptoms: fatigue, acid reflux, poor sleep, noisy

[0064] The four levels of main symptoms of single TCM symptoms, namely none, mild, moderate and severe, are scored as 0, 2, 4 and 6 points respectively; the four levels of secondary symptoms, namely none, mild, moderate and severe, are scored as 0, 1, 2 and 3 points respectively.

[0065] ②Grading standard of atrophy degree

[0066] A decrease in the number of intrinsic glands ≤ 1 / 3 was mild, a decrease in the number of intrinsic glands 1 / 3 < ≤ 2 / 3 was moderate, and a decrease in the number of intrinsic glands > 2 / 3 was severe. Before and after treatment, the patients underwent gastroscopy (≥ 1 year from the last gastroscopy). When suspicious lesions were observed during gastroscopy, a biopsy (pathological examination) was taken. However, no biopsy was taken if no suspicious lesions were found during gastroscopy. The atrophy of the gastric intrinsic glands in the two groups was statistically analyzed.

[0067] 7.3 Criteria for determining efficacy

[0068] 1) Criteria for determining efficacy of TCM syndromes

[0069] According to the nimodipine method, the efficacy index (CI) = (pre-treatment score - post-treatment score) ÷ pre-treatment score X 100%.

[0070] ①Clinical recovery: the symptom score decreases significantly, CI ≥ 95%;

[0071] ② Significantly effective: The symptom score decreased significantly, 70%≤CI<95%;

[0072] ③ Effective: The symptom score decreased significantly, 30%≤CI<70%;

[0073] ④ Ineffective: The symptom score decreased slightly or did not decrease, CI < 30%.

[0074] 2) Total effective rate = (number of clinically cured cases + number of markedly effective cases + number of effective cases) / total number of cases

[0075] 3) Safety evaluation standards

[0076] ① Level 1: No adverse reactions occurred and safety indicators were normal;

[0077] ② Level 2: Mild adverse reactions occurred, but safety indicators were normal;

[0078] ③Level 3: Moderate adverse reactions occur or safety indicators are abnormal;

[0079] ④Level 4: There are serious adverse reactions or safety indicators are obviously abnormal.

[0080] 7.4 Statistical analysis

[0081] Statistical analysis will be performed using SPSS 25.0 statistical analysis software. All statistical tests were performed using two-sided tests. P>0.05 was considered to be insignificant, P<0.05 was considered to be statistically significant, and P<0.01 was considered to be statistically significant.

[0082] The measurement data of the two groups of subjects will be expressed as mean ± standard deviation. Statistical description was performed. For data that met normality and variance homogeneity, the t test was used, while for data that did not meet normality and variance homogeneity and for comparison of rank data, the rank sum test was used. P < 0.05 was considered statistically significant.

[0083] 8. Research Results

[0084] 8.1 Included cases

[0085] A total of 80 cases were included in this study, and after exclusion according to the exclusion criteria, there were 75 valid cases. The gender, age, TCM symptom score, gastroscopy efficacy evaluation, and efficacy evaluation of the 75 patients were analyzed separately.

[0086] 8.2 Comparison of gender, age, and disease course between the two groups

[0087] Table 1 Comparison of gender between the two groups of patients

[0088]

[0089] Table 2 Comparison of age between the two groups of patients

[0090]

[0091] Table 3 Comparison of disease course between the two groups

[0092]

[0093] Gender of patients in the two groups 2 The t-test showed that P>0.05 showed no significant difference, indicating that there was no difference in gender distribution between the two groups, and the genders were balanced and comparable. The age and course of disease between the two groups were tested by t-test, P>0.05, and there was no significant difference, indicating that there was no difference in age and course of disease between the two groups, and the age and course of disease were balanced and comparable.

[0094] 8.3 Comparison of total TCM symptom scores between the two groups before and after treatment

[0095] Table 4 Comparison of total score of TCM syndrome before and after treatment

[0096]

[0097] Before treatment, the total scores of TCM symptoms in the two groups were compared by t-test, P>0.05, and the difference was not statistically significant, indicating that the TCM symptoms of the two groups were balanced and comparable before treatment; after treatment, the total scores of TCM symptoms in the two groups were compared by t-test, P<0.05, which was statistically significant, indicating that the treatment group was significantly better than the control group in the degree of improvement in TCM syndrome scores.

[0098] 8.4 Comparison of TCM efficacy between the two groups before and after treatment

[0099] Table 5 Comparison of TCM efficacy between the two groups after treatment

[0100]

[0101] The efficacy of traditional Chinese medicine in the two groups of patients before and after treatment 2 Test, P < 0.01, which is statistically significant, indicating that the treatment group is significantly better than the control group in terms of TCM efficacy.

[0102] 8.5 Comparison of TCM efficacy between the two groups before and after treatment

[0103] Table 6 Comparison of the degree of atrophy of gastric glands between the two groups

[0104]

[0105] Before treatment, the degree of atrophy of the gastric glands in the two groups was compared by rank sum test, P=0.968>0.05, and the difference was not statistically significant, indicating that the degree of atrophy of the gastric glands in the two groups was balanced and comparable before treatment; after treatment, the degree of atrophy of the gastric glands in the two groups was compared by rank sum test, P=0.000<0.01, which was statistically significant, indicating that the treatment group was significantly better than the control group in improving the degree of atrophy of the gastric glands.

Claims

1. A Chinese medicine composition for treating chronic atrophic gastritis, characterized in that: The composition is composed of Chinese medicinal materials in the following weight proportions: 12-18g of Blumea balsamifera, 15-25g of Radix Achyranthis Bidentatae, 15-25g of Rhizoma Cyperi, 8-12g of Patchouli, 8-12g of Alpinia officinalis, 2-4g of Notoginseng, 2-4g of Aquilaria wood, 8-12g of Phragmites australis, and 8-12g of Chicken Gizzard Stone.

2. A Chinese medicine composition for treating chronic atrophic gastritis according to claim 1, characterized in that: The composition is composed of Chinese medicinal materials in the following weight proportions: 14-16g of Blumea balsamifera, 19-21g of Radix Achyranthis Bidentatae, 19-21g of Rhizoma Cyperi, 9-11g of Patchouli, 9-11g of Alpinia officinalis, 2.5-3.5g of Notoginseng, 2.5-3.5g of Aquilaria woodis, 9-11g of Phragmites australis, and 9-11g of Chicken Gizzard Stone.

3. A Chinese medicine composition for treating chronic atrophic gastritis according to claim 2, characterized in that: It is composed of Chinese medicinal materials in the following weight proportions: 15g of Blumea balsamifera, 20g of Radix Achyranthis Bidentatae, 20g of Rhizoma Cyperi, 10g of Patchouli, 10g of Alpinia officinalis, 3g of Notoginseng, 3g of Aquilaria wood, 10g of Rhizoma Phragmites, and 10g of Chicken Gizzard Stone.

4. A Chinese medicine extract for treating chronic atrophic gastritis, characterized in that: Prepared from the Chinese medicine composition according to any one of claims 1 to 3.

5. A Chinese medicine extract for treating chronic atrophic gastritis according to claim 4, characterized in that: The preparation method of the traditional Chinese medicine extract comprises the following steps: weighing each component according to the traditional Chinese medicine formula, grinding agarwood into powder, adding water to other components until the raw medicine is covered, soaking for 30 to 40 minutes, boiling over high heat, then decocting over low heat for 20 to 30 minutes after boiling, repeating the decocting 2 to 3 times, mixing the medicinal juice, adding agarwood powder, and stirring to obtain the extract.

6. Use of the Chinese medicine composition according to any one of claims 1 to 3 or the Chinese medicine extract according to any one of claims 4 to 5 in the preparation of a drug for treating chronic atrophic gastritis.

Images